Higher Fasting Pretransplant C-peptide Levels in Type 2 Diabetics Undergoing Simultaneous Pancreas-kidney Transplantation Are Associated With Posttransplant Pancreatic Graft Dysfunction.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
medline:
4
4
2023
pubmed:
28
1
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
Among selected patients with type 2 diabetes mellitus (T2DM), simultaneous pancreas and kidney (SPK) transplants can be an effective option. However, data are limited about outcomes in T2DM SPK recipients based on the pretransplant C-peptide levels. In this study, we reviewed all T2DM SPK recipients and categorized them based on the pretransplant fasting C-peptide levels into 3 groups: low (≤2 ng/mL), medium (>2-8 ng/mL), and high (>8 ng/mL). Several measures of graft failures (GFs), graft dysfunction, and composite outcomes were of interest. There were a total of 76 SPK recipients (low, n = 14; medium, n = 47; high, n = 15). At the last follow-up, the low group did not reach any outcome; in contrast, 11 (23%) in the medium group and 5 (33%) in the high group reached the uncensored composite outcome; 6 (13%) in the medium group and 2 (13%) in the high group had GF; and 8 (17%) in the medium group and 4 (26.7%) in the high group reached the death-censored composite outcomes. In a fully adjusted model, each pretransplant C-peptide unit was not associated with an increased risk of the composite outcome, GF, or death-censored composite outcomes. However, in multivariate analysis with limited adjustment, pretransplant C-peptide was associated with the composite outcome (hazard ratio: 1.18, 95% confidence interval, 1.01-1.38; P = 0.03) and death-censored composite outcome (hazard ratio: 1.20; 95% confidence interval, 1.01-1.42; P = 0.03). Although limited by the small sample size, we found excellent outcomes among T2DM SPK recipients overall. However, higher levels of pretransplant C-peptide may be associated with inferior posttransplant outcomes that include graft dysfunction.
Sections du résumé
BACKGROUND
Among selected patients with type 2 diabetes mellitus (T2DM), simultaneous pancreas and kidney (SPK) transplants can be an effective option. However, data are limited about outcomes in T2DM SPK recipients based on the pretransplant C-peptide levels.
METHODS
In this study, we reviewed all T2DM SPK recipients and categorized them based on the pretransplant fasting C-peptide levels into 3 groups: low (≤2 ng/mL), medium (>2-8 ng/mL), and high (>8 ng/mL). Several measures of graft failures (GFs), graft dysfunction, and composite outcomes were of interest.
RESULTS
There were a total of 76 SPK recipients (low, n = 14; medium, n = 47; high, n = 15). At the last follow-up, the low group did not reach any outcome; in contrast, 11 (23%) in the medium group and 5 (33%) in the high group reached the uncensored composite outcome; 6 (13%) in the medium group and 2 (13%) in the high group had GF; and 8 (17%) in the medium group and 4 (26.7%) in the high group reached the death-censored composite outcomes. In a fully adjusted model, each pretransplant C-peptide unit was not associated with an increased risk of the composite outcome, GF, or death-censored composite outcomes. However, in multivariate analysis with limited adjustment, pretransplant C-peptide was associated with the composite outcome (hazard ratio: 1.18, 95% confidence interval, 1.01-1.38; P = 0.03) and death-censored composite outcome (hazard ratio: 1.20; 95% confidence interval, 1.01-1.42; P = 0.03).
CONCLUSIONS
Although limited by the small sample size, we found excellent outcomes among T2DM SPK recipients overall. However, higher levels of pretransplant C-peptide may be associated with inferior posttransplant outcomes that include graft dysfunction.
Identifiants
pubmed: 36706060
doi: 10.1097/TP.0000000000004489
pii: 00007890-202304000-00027
doi:
Substances chimiques
C-Peptide
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e109-e121Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
J.O. receives clinical trial support from Veloxis, Vertex, CareDx, and Natera. S.P. receives clinical trial support from Veloxis pharmaceuticals. The other authors declare no conflicts of interest.
Références
Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease among persons with diabetes--United States, 1990-2002. MMWR Morbidity Mortality Weekly Rep. 2005;54:1097–1100
National Kidney Foundation. Diabetes and Chronic Kidney Disease. 2016. Available at https://www.kidney.org/news/newsroom/factsheets/Diabetes-And-CKD#:~:text=Diabetes%20is%20the%20leading%20cause%20of%20kidney%20failure%2C,reduction%20of%20dietary%20protein%20intake%20are%20also%20important . Accessed May 16, 2022.
Orlando G, Stratta RJ, Light J. Pancreas transplantation for type 2 diabetes mellitus. Curr Opin Organ Transplant. 2011;16:110–115.
Narres M, Claessen H, Droste S, et al. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PLoS One. 2016;11:e0147329.
Chang YT, Wu JL, Hsu CC, et al. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998-2009. Diabetes Care. 2014;37:277–285.
Wang AY. Cardiovascular risk in diabetic end-stage renal disease patients. J Diabetes. 2011;3:119–131.
Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015;20:94–102.
Papageorge CM, Bolognese AC, Odorico JS. Expanding access to pancreas transplantation for type 2 diabetes mellitus. Curr Opin Organ Transplant. 2021;26:390–396.
Light J, Tucker M. Simultaneous pancreas kidney transplants in diabetic patients with end-stage renal disease: the 20-yr experience. Clin Transplant. 2013;27:E256–E263.
Stratta RJ, Rogers J, Farney AC, et al. Pancreas transplantation in C-peptide positive patients: does “type” of diabetes really matter? J Am Coll Surg. 2015;220:716–727.
Kaufman DB, Sutherland DE. Simultaneous pancreas-kidney transplants are appropriate in insulin-treated candidates with uremia regardless of diabetes type. Clin J Am Soc Nephrol. 2011;6:957–959.
Sampaio MS, Kuo HT, Bunnapradist S. Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. Clin J Am Soc Nephrol. 2011;6:1198–1206.
Pham PH, Stalter LN, Martinez EJ, et al. Single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes. Am J Transplant. 2021;21:2810–2823.
OPTN UNOS: Pancreas Committee. Definition of Pancreas Graft Failure. 2015. Available at https://unos.org/wp-content/uploads/Definition-of-Pancreas-Graft-Failure.pdf . Accessed May 16, 2022.
Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant. 2007;7:303–308.
Li X, Zhou ZG, Qi HY, et al. [Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function]. Zhong Nan Da Xue Bao Yi Xue Ban. 2004;29:419–423.
Parajuli S, Alagusundaramoorthy S, Aziz F, et al. Outcomes of pancreas transplant recipients with de novo donor-specific antibodies. Transplantation. 2019;103:435–440.
Parajuli S, Arunachalam A, Swanson KJ, et al. Outcomes after simultaneous kidney-pancreas versus pancreas after kidney transplantation in the current era. Clin Transplant. 2019;33:e13732.
Axelrod DA, Sung RS, Meyer KH, et al. Systematic evaluation of pancreas allograft quality, outcomes and geographic variation in utilization. Am J Transplant. 2010;10:837–845.
Gurram V, Gurung K, Rogers J, et al. Do pretransplant C-peptide levels predict outcomes following simultaneous pancreas-kidney transplantation? A matched case-control study. Clin Transplant. 2022;36:e14498.
Sener A, Cooper M, Bartlett ST. Is there a role for pancreas transplantation in type 2 diabetes mellitus? Transplantation. 2010;90:121–123.
Light JA, Sasaki TM, Currier CB, et al. Successful long-term kidney-pancreas transplants regardless of C-peptide status or race. Transplantation. 2001;71:152–154.
Nordheim E, Birkeland KI, Åsberg A, et al. Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. Eur J Endocrinol. 2018;179:251–259.
Xie WY, McAlister VC, Fiorini K, et al. Elevated C-peptide levels are associated with acute rejection in kidney pancreas transplantation. Transplant Proc. 2020;52:987–991.
Ward C, Odorico JS, Rickels MR, et al. International survey of clinical monitoring practices in pancreas and islet transplantation. Transplantation. 2022;106:1647–1655.